ADCs, psychedelics & biotech IPOs: BioCentury’s latest podcast

Plus: Gilead’s $4.3B takeout of CymaBay

Innate immunity is getting another shot at cancer through antibody-drug conjugates, with immunostimulatory antibody-drug conjugates moving from concept to clinical product. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the therapies work and what sets them apart from conventional ADCs.

The editors also survey the small group of companies developing psychedelic therapies that aim to overcome the difficulties of the business model.

Finally, the editors assess the $4.3 billion takeout of liver disease company CymaBay Therapeutics Inc. (NASDAQ:CBAY) by  Gilead Sciences Inc. (NASDAQ:GILD), and the performance of IPOs by genomic editing tools company Metagenomi Inc. (NASDAQ:MGX) and immunology company Kyverna Therapeutics Inc. (NASDAQ:KYTX).

Join BioCentury, BayHelix and McKinsey March 4-6 in Singapore for the third East-West Biopharma Summit. For information on how to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at conferences@biocentury.com.